Scynexis planning Phase III program for vulvovaginal candidiasis candidate

Scynexis Inc. (NASDAQ:SCYX) said all five dose regimens of oral SCY-078 showed "meaningful clinical and mycological activity" in the double-blind, U.S. Phase IIb DOVE trial in 186

Read the full 275 word article

User Sign In